Clinical trials: Activation, Patient
NSCLC Patients With EGFR Activating Mutation
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
The current first line treatment of patients with EGFR activating mutation lung cancer is EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of response rate and progression-free survival.
- Trial name
- FLARE (NCT02178397)
- Testing
- ERLOTINIB WITH CHEMOTHERAPY, CHEMOTHERAPY ONLY
- Where
- 35 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Francois Baclesse
Rheumatoid Arthritis, Cardiovascular Diseases
Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:
One of the greatest success stories in rheumatology - the achievement of rheumatoid arthritis (RA) remission - is tempered by the fact that individuals with RA are dramatically under evaluated and under treated to reduce the risk…
- Conditions
- Rheumatoid Arthritis, Cardiovascular Diseases, Hyperlipidemias
- Trial name
- CARE RA (NCT04488497)
- Testing
- Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis, Standard of care
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Lung Cancer
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Advanced stage lung cancer is generally treated with anti-cancer medication called chemotherapy. Most lung cancer is caused by cigarette smoking.
- Trial name
- NCT00988169
- Testing
- oral erlotinib and pulsed doses of oral AT-101
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stroke
Telestroke Triage in Suspected Stroke Patients
The ASTRAL trial is a randomized study in patients with suspected stroke in the ambulance setting. The study evaluates whether prehospital telestroke consultation, in addition to standard care, can reduce unnecessary stroke code…
- Trial name
- ASTRAL (NCT07657117)
- Testing
- Telestroke triage, Standard Care (in control arm)
- Where
- Netherlands
- Volunteers
- 518 people
- Sponsor
- Nyika D. Kruyt
Irritable Bowel Syndrome
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients
Despite the pathophysiology of IBS remains largely unsettled, several mechanisms have been proposed to explain symptom generation.
- Trial name
- CMD-IBS09(2) (NCT01370720)
- Testing
- Recoclix
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MARIA CRISTINA COMELLI
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
COPD
Morphological Parameters of Blood Cell's Activation in Characterization and Prognosis in a COPD Patients Cohort
Though exacerbations in the COPD (Chronic Pulmonary Obstructive Disease) and specially the most severe cases (hospitalizations) are currently a fundamental outcome in the COPD due to its clinical and economic significance, there…
- Trial name
- NCT04923360
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Hospital Galdakao-Usansolo
Heart Failure
Patient Activation in High-Risk Patients With Heart Failure
The purpose of this study was to determine the efficacy of a self-management program, called the Heart PACT Program, compared to usual health care in patients with heart failure.
- Trial name
- HeartPACT (NCT00260650)
- Testing
- Heart PACT Program
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- VA Office of Research and Development
Wounds
A Post-marketing Observational Study of Cell Therapy for Chronic Wounds
A post-marketing multi-center observational study to provide data describing the safety and effectiveness of CUREXCELL™ as it is applied in a real-life setting for treatment in patients with chronic and/or refractory wounds.
- Trial name
- NCT01038986
- Testing
- CureXcell
- Where
- 3 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Macrocure Ltd.
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis
Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Hemophagocytic Syndromes
- Trial name
- FERRITS (NCT02854943)
- Volunteers
- 2,623 people
- Sponsor
- Gunnar Lachmann
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm
- Trial name
- NCT03213691
- Testing
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Glaucoma, Health Literacy
Nurse-led Educational Intervention on Patients With Glaucoma With Low Health Literacy
Introduction: Chronic diseases are a major cause of ill health, disability and death worldwide and are potentially preventable and treatable.
- Conditions
- Glaucoma, Health Literacy, Patient Activation
- Trial name
- NCT06706089
- Testing
- Nurse-led educational intervention
- Where
- Greece
- Volunteers
- 312 people
- Sponsor
- Hellenic Mediterranean University
COPD Exacerbation
Health Literacy Activation RCT Among the COPD Patients and Designated Support Dyad
This study investigates whether increasing health literacy among COPD patients and their designated health coach during a hospital admission caused by symptoms exacerbation will lead to better health outcomes including increased…
- Trial name
- NCT03721315
- Testing
- Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Albert Einstein Healthcare Network
Chronic Kidney Disease, Uremic Pruritus
The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus.
This study aims to evaluate the efficacy and safety of probiotics versus activated charcoal in management of chronic kidney disease patients suffering from uremic pruritus.
- Trial name
- NCT06579066
- Testing
- Probiotic Blend Capsule, Activated Charcoal
- Volunteers
- 123 people
- Sponsor
- Ain Shams University
Intracranial Hypertension, Cerebral Edema
Coagulation Activation by Hyperosmolar Agents in Intracranial Hypertension
Osmotherapy consists in the therapeutic use of osmotically active substances with the aim of reducing the volume and therefore the intracranial pressure.
- Trial name
- NCT03409237
- Testing
- Mannitol, Hypertonic saline solution
- Where
- Italy
- Sponsor
- Neuromed IRCCS
Type 2 Diabetes
INVESTIGATION OF THE EFFECT OF DIFFERENT ACTIVATION TECHNIQUES ON TLR9, IL6, IL10, TNF-ALFA LEVELS IN HEALTHY AND TYPE 2 DIABETIC PATIENTS WITH APICAL PERIODONTITIS REQUIRING RETREATMENT
The subject of this thesis study is the effects of SWEEPS laser and ultrasonic activation methods on the immune response in the treatment of apical periodontitis in healthy individuals and patients with Type 2 diabetes requiring…
- Trial name
- TLR9 in T2DM (NCT07389772)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- bengisu yüksel
Breast Cancer
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2…
- Trial name
- NCT01048099
- Testing
- PRO Onc Assay and Treatment, Trastuzumab, Pertuzumab
- Where
- 7 sites in United States
- Volunteers
- 283 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Malignant Solid Tumor
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.
- Trial name
- NCT05098405
- Testing
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- Where
- 4 sites in France, Netherlands
- Volunteers
- 46 people
- Sponsor
- Molecular Partners AG
Tourette's Syndrome, Chronic Motor Tic Disorder
Brain Activation in Vocal and Motor Tics
This study will investigate the brain areas that are activated by vocal and motor tics in patients with Tourette's syndrome and other tic disorders. Tics are involuntary repetitive movements similar to voluntary movements.
- Conditions
- Tourette's Syndrome, Chronic Motor Tic Disorder, Chronic Motor Vocal Disorder
- Trial name
- NCT00026000
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)